This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.
DaVita (DVA) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DaVita (DVA) gains from international revenues in Q1.
DaVita HealthCare (DVA) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -4.21% and -2.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
Fresenius Medical's New Hemodialysis Software Gets FDA Nod
by Zacks Equity Research
Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.
Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
by Zacks Equity Research
Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.
DaVita HealthCare (DVA) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Consider DaVita (DVA) Stock Now?
by Zacks Equity Research
Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why Investors Should Hold DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) steadily expands in international markets. Moreover, the company has witnessed Dialysis services in the United States lately.
New Strong Sell Stocks for February 19th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Stock Market News For Feb 14, 2019
by Zacks Equity Research
Wall Street rally continued in Wednesday buoyed by positive developments on the trade war front.
DaVita (DVA) Q4 Earnings Beat and Revenues Miss Estimates
by Zacks Equity Research
DaVita's (DVA) Q4 results gain from increasing dialysis services in and outside the United States.
DaVita HealthCare (DVA) Tops Q4 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 1.12% and -5.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects headwinds in DaVita Rx, while overseas prospects of the dialysis business look bright.
Analysts Estimate DaVita HealthCare (DVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
DaVita HealthCare (DVA) Down 11.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Falling Estimates & Price Mean for DaVita (DVA)
by Zacks Equity Research
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.
DaVita's (DVA) Q3 Earnings Lag Estimates, Kidney Care Down
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in Q3; 2018 guidance narrowed.
DaVita HealthCare (DVA) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -37.08% and -2.47%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?